Related Experiment Video
Updated: Jun 14, 2026
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells
David Marc Davies1, John Maher
1King's College London School of Medicine, Research Oncology Section, Division of Cancer Studies, Third Floor Bermondsey Wing, Guy's Hospital Campus, St Thomas Street, London SE1 9RT, UK.
Abstract:
Harnessing the power of the immune system to target cancer has long been a goal of tumor immunologists. One avenue under investigation is the modification of T cells to express a chimeric antigen receptor (CAR). Expression of such a receptor enables T-cell specificity to be redirected against a chosen tumor antigen. Substantial research in this field has been carried out, incorporating a wide variety of malignancies and tumor-associated antigens. Ongoing investigations will ensure this area continues to expand at a rapid pace. This review will explain the evolution of CAR technology over the last two decades in addition to detailing the associated benefits and disadvantages. The outcome of recent phase I clinical trials and the impact that these have had upon the direction of future research in this field will also be addressed.
Insights
Chimeric antigen receptor (CAR) T-cell therapy engineers immune cells to fight cancer. This review details CAR T-cell evolution, benefits, drawbacks, and recent clinical trial impacts on future research.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cancer immunotherapy aims to leverage the immune system against tumors.
- Chimeric antigen receptor (CAR) T-cell therapy is a promising approach.
- CARs redirect T-cell specificity towards tumor antigens.
Purpose of the Study:
- To review the evolution of CAR T-cell technology over the past 20 years.
- To detail the benefits and disadvantages of CAR T-cell therapy.
- To discuss the impact of recent clinical trials on future research directions.
Main Methods:
- Literature review of CAR T-cell technology.
- Analysis of existing research across various malignancies and tumor antigens.
- Evaluation of outcomes from phase I clinical trials.
Main Results:
- CAR T-cell technology has evolved significantly.
- The therapy shows promise but has associated benefits and drawbacks.
- Recent clinical trials are shaping future research trajectories.
Conclusions:
- CAR T-cell therapy represents a rapidly advancing field in cancer treatment.
- Continued research is essential to optimize efficacy and address challenges.
- Clinical trial outcomes guide the future development of this immunotherapy.
